Why the drug development pipeline is not delivering better medicines.
LSE Health, Department of Social Policy, London School of Economics and Political Science, London, UK h.naci@lse.ac.uk.
Huseyin
H
Naci
Institute of Global Health Innovation, Imperial College London.
Alexander W
AW
Carter
LSE Health, Department of Social Policy, London School of Economics and Political Science, London, UK.
Elias
E
Mossialos
D003365:Costs and Cost Analysis; D017277:Drug Approval / Q000191:economics / Q000379:methods; D004345:Drug Industry / Q000379:methods / Q000458:organization & administration; D004335:Drug and Narcotic Control / Q000379:methods / Q000458:organization & administration; D005060:Europe; D033161:Government Regulation; D006801:Humans; D008389:Marketing of Health Services / Q000379:methods; D054539:Medication Therapy Management / Q000191:economics* / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data; D014481:United States